Abstract
Background
Clinical trials comparing incretin-based therapies-glucagon-like peptide-1 receptor agonists (exenatide-twice daily and once weekly-and once-daily liraglutide) and dipeptidyl peptidase-4 inhibitors (vildagliptin, sitagliptin, saxagliptin and linagliptin)-with placebo and oral antidiabetic drugs show that these therapies effectively control glycaemia, with low risk of hypoglycaemia. Glucagon-like peptide-1 receptor agonists are associated with weight loss and reductions in systolic blood pressure, while dipeptidyl peptidase-4 inhibitors are weight-neutral. Based on this, the National Institute for Health and Clinical Excellence recommends using these agents in patients with type 2 diabetes for whom excess weight and/or hypoglycaemia are problematic.Aim of the review
This review aims to help decision making when selecting and using incretin-based therapies in type 2 diabetes.Methods
A search or MEDLINE and Cochrane clinical trials databases, limited to clinical trials in humans, was performed using the search criteria 'exenatide or liraglutide or vildagliptin or sitagliptin, or saxagliptin or linagliptin'. Abstracts presented at recent American Diabetes Association and European Association for the Study of Diabetes meetings were also searched. Eighteen clinical trials directly comparing incretin-based therapies were identified.Results
Glucagon-like peptide-1 receptor agonists achieved significantly greater reductions in glycated hemoglobin and weight than dipeptidyl peptidase-4 inhibitors, which have a neutral effect on weight. Between-treatment differences were clinically important. Gastrointestinal side effects were more frequent with glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors. Comparisons between glucagon-like peptide-1 receptor agonists and between dipeptidyl peptidase-4 inhibitors showed that differences within the available agents in the two sub-classes are small. Greater treatment satisfaction was reported with glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors.Conclusion
Glucagon-like peptide-1 receptor agonists achieve greater glycated hemoglobin reductions than dipeptidyl peptidase-4 inhibitors, with concomitant weight loss. Probably due to the greater efficacy of glucagon-like peptide-1 receptor agonists, patient satisfaction is greater with these agents compared with dipeptidyl peptidase-4 inhibitors despite injectable versus oral administration and more frequent gastrointestinal side effects with the agonists.References
Articles referenced by this article (74)
The International Diabetes Federation. IDF Diabetes Atlas. 4th ed. 2009. Available from: http://www.diabetesatlas.org/content/international-diabetes-federation . Accessed 9 May 2012.
Diabetes UK. Publications, reports and resources: Reports and statistics (Diabetes prevalence 2010). 2010. Available from: http://www.diabetes.org.uk/Professionals/Publications-reports-and-resources/Reports-statistics-and-case-studies/Reports/Diabetes-prevalence-2010 . Accessed 9 May 2011.
Trends in the prevalence and incidence of diabetes in the UK: 1996-2005.
J Epidemiol Community Health, (4):332-336 2009
MED: 19240084
Bergenstal RM, Kendall DM. Management of type 2 diabetes: a systematic approach to meeting the standards of care: oral agents, insulin, and management of complications. In: Degroot LJ, Jameson JL, editors. Endocrinology. Philadelphia, PA: Saunders; 2001. p. 821–35.
UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44(11):1249–58.
Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev. 1999;7(3):139–53.
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
BMJ, (7258):405-412 2000
MED: 10938048
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
N Engl J Med, (23):2427-2443 2006
MED: 17145742
Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
JAMA, (3):360-372 2002
MED: 11790216
Show 10 more references (10 of 74)
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Smart citations by scite.ai
Explore citation contexts and check if this article has been
supported or disputed.
https://scite.ai/reports/10.1007/s11096-012-9729-9
Article citations
Alternate-day fat diet and exenatide modulate the brain leptin JAK2/STAT3/SOCS3 pathway in a fat diet-induced obesity and insulin resistance mouse model.
Arch Med Sci, 19(5):1508-1519, 01 Feb 2023
Cited by: 3 articles | PMID: 37732053 | PMCID: PMC10507768
A glucagon-like peptide-1 receptor antagonist reduces the insulin response to a glycemic meal in ponies.
J Anim Sci, 101:skad389, 01 Jan 2023
Cited by: 0 articles | PMID: 38066683 | PMCID: PMC10724109
Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control.
Clin Med Insights Endocrinol Diabetes, 14:11795514211051698, 28 Oct 2021
Cited by: 9 articles | PMID: 34733107 | PMCID: PMC8558587
Review Free full text in Europe PMC
Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.
J Korean Med Sci, 33(41):e258, 05 Sep 2018
Cited by: 0 articles | PMID: 30288156 | PMCID: PMC6170670
A health state utility valuation study to assess the impact of treatment mode of administration in Gaucher disease.
Orphanet J Rare Dis, 13(1):159, 10 Sep 2018
Cited by: 3 articles | PMID: 30201003 | PMCID: PMC6131903
Review Free full text in Europe PMC
Go to all (44) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Ann Pharmacother, 45(7-8):850-860, 05 Jul 2011
Cited by: 34 articles | PMID: 21730278
Review
Recent advances in incretin-based therapies.
Clin Endocrinol (Oxf), 77(4):489-499, 01 Oct 2012
Cited by: 33 articles | PMID: 22804841
Review
Efficacy and safety of incretin based therapies: clinical trial data.
J Am Pharm Assoc (2003), 49 Suppl 1:S30-40, 01 Sep 2009
Cited by: 28 articles | PMID: 19801363
Review
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Am J Manag Care, 16(7 suppl):S187-94, 01 Aug 2010
Cited by: 20 articles | PMID: 20809667
Review
Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.
Diabetes Obes Metab, 14(10):882-892, 17 Apr 2012
Cited by: 35 articles | PMID: 22420869
Review